Nifty
Sensex
:
:
25514.30
83021.75
286.35 (1.14%)
989.94 (1.21%)

Pharmaceuticals & Drugs - Global

Rating :
78/99

BSE: 532296 | NSE: GLENMARK

2608.50
19-Nov-2026
  • Open
  • High
  • Low
  • Previous Close
  •  2655.8
  •  2666.7
  •  2608.5
  •  2646.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  392816
  •  1034326332.2
  •  2714
  •  1825.1

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 73,971.09
  • 50.97
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 73,546.93
  • 0.10%
  • 6.60

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.65%
  • 2.58%
  • 10.44%
  • FII
  • DII
  • Others
  • 21.51%
  • 16.49%
  • 2.33%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.46
  • 6.66
  • 12.86

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.42
  • 14.53
  • 30.78

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 2.08
  • 7.66
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.64
  • 13.84
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.16
  • 3.73
  • 5.17

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.28
  • 12.61
  • 16.42

Earnings Forecasts:

(Updated: 14-11-2026)
Description
2026
2027
2028
2029
Adj EPS
48.26
76.16
94.93
111.23
P/E Ratio
54.05
34.25
27.48
23.45
Revenue
16711.4
16863.7
18879.5
20989
EBITDA
4213.25
3549.76
4235.02
4766.91
Net Income
1361.85
2155.53
2679.03
3138.7
ROA
7.57
16.03
-
-
P/B Ratio
7.00
5.90
4.97
4.19
ROE
14.07
18.15
19.25
18.79
FCFF
1917.71
719.64
1576.68
2151.16
FCFF Yield
2.57
0.97
2.12
2.89
Net Debt
-582.73
-882.73
-1837.57
-2508.7
BVPS
372.5
441.88
524.72
622.31

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 26
Sep 25
Var%
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Net Sales
4,247.33
6,046.87
-29.76%
4,018.48
3,264.44
23.10%
3,770.59
3,256.21
15.80%
3,900.62
3,387.55
15.15%
Expenses
3,383.52
3,687.32
-8.24%
3,213.69
2,683.92
19.74%
3,007.99
2,695.18
11.61%
3,030.87
2,787.32
8.74%
EBITDA
863.80
2,359.55
-63.39%
804.80
580.52
38.63%
762.60
561.03
35.93%
869.75
600.23
44.90%
EBIDTM
20.34%
39.02%
20.03%
17.78%
20.22%
17.23%
22.30%
17.72%
Other Income
2.54
200.63
-98.73%
65.76
26.44
148.71%
189.08
11.68
1,518.84%
44.46
31.13
42.82%
Interest
63.77
66.46
-4.05%
54.00
58.23
-7.26%
42.60
66.71
-36.14%
41.43
52.29
-20.77%
Depreciation
180.42
141.20
27.78%
173.17
129.93
33.28%
147.91
125.20
18.14%
154.45
122.74
25.84%
PBT
338.29
967.40
-65.03%
643.39
95.58
573.14%
387.77
7.97
4,765.37%
534.00
456.33
17.02%
Tax
74.46
356.97
-79.14%
160.56
48.61
230.30%
86.45
3.59
2,308.08%
130.77
108.30
20.75%
PAT
263.83
610.43
-56.78%
482.83
46.97
927.95%
301.32
4.38
6,779.45%
403.23
348.03
15.86%
PATM
6.21%
10.10%
12.02%
1.44%
7.99%
0.13%
10.34%
10.27%
EPS
9.35
21.63
-56.77%
17.11
1.66
930.72%
10.68
0.16
6,575.00%
14.29
12.33
15.90%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
15,937.02
16,982.51
13,321.74
11,813.10
11,583.24
12,304.90
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
Net Sales Growth
-0.11%
27.48%
12.77%
1.98%
-5.86%
12.44%
2.85%
7.86%
8.72%
-0.05%
 
Cost Of Goods Sold
5,018.72
4,687.07
4,287.37
4,352.00
4,204.38
4,312.08
3,620.18
3,623.78
3,283.71
2,963.32
2,552.03
Gross Profit
10,918.30
12,295.44
9,034.37
7,461.10
7,378.85
7,992.82
7,323.75
7,017.18
6,581.76
6,111.10
6,527.39
GP Margin
68.51%
72.40%
67.82%
63.16%
63.70%
64.96%
66.92%
65.94%
66.72%
67.34%
71.89%
Total Expenditure
12,636.07
12,410.09
10,970.36
10,617.77
9,948.23
9,984.60
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
Power & Fuel Cost
-
134.13
131.40
124.00
111.75
200.64
164.67
173.69
165.25
137.47
127.02
% Of Sales
-
0.79%
0.99%
1.05%
0.96%
1.63%
1.50%
1.63%
1.68%
1.51%
1.40%
Employee Cost
-
3,577.85
3,022.06
2,868.14
2,600.78
2,447.42
2,343.71
2,254.78
2,056.07
1,871.84
1,640.81
% Of Sales
-
21.07%
22.69%
24.28%
22.45%
19.89%
21.42%
21.19%
20.84%
20.63%
18.07%
Manufacturing Exp.
-
763.17
767.88
1,012.86
633.51
784.63
638.74
669.50
725.16
648.59
546.75
% Of Sales
-
4.49%
5.76%
8.57%
5.47%
6.38%
5.84%
6.29%
7.35%
7.15%
6.02%
General & Admin Exp.
-
1,758.14
1,457.32
1,313.59
1,212.13
1,264.86
1,027.60
1,168.32
891.10
526.29
1,022.89
% Of Sales
-
10.35%
10.94%
11.12%
10.46%
10.28%
9.39%
10.98%
9.03%
5.80%
11.27%
Selling & Distn. Exp.
-
1,431.79
1,270.52
892.72
1,137.20
896.31
943.21
1,005.63
1,125.08
996.99
1,064.70
% Of Sales
-
8.43%
9.54%
7.56%
9.82%
7.28%
8.62%
9.45%
11.40%
10.99%
11.73%
Miscellaneous Exp.
-
57.94
33.81
54.46
48.49
78.68
121.44
47.19
33.29
314.55
1,064.70
% Of Sales
-
0.34%
0.25%
0.46%
0.42%
0.64%
1.11%
0.44%
0.34%
3.47%
0.97%
EBITDA
3,300.95
4,572.42
2,351.38
1,195.33
1,635.01
2,320.30
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
EBITDA Margin
20.71%
26.92%
17.65%
10.12%
14.12%
18.86%
19.05%
15.96%
16.07%
17.80%
22.43%
Other Income
301.84
460.62
113.72
839.99
288.90
166.67
50.22
159.60
208.14
91.40
37.37
Interest
201.80
208.72
207.06
515.97
349.04
298.10
353.11
377.32
334.58
285.57
237.32
Depreciation
655.95
573.48
486.01
581.91
569.17
486.71
443.55
417.17
325.90
301.88
264.37
PBT
1,903.45
4,250.83
1,772.03
937.45
1,005.70
1,702.16
1,337.93
1,063.20
1,133.45
1,119.33
1,572.38
Tax
452.24
622.79
352.07
1,867.35
329.40
447.60
412.39
320.11
375.64
315.46
382.68
Tax Rate
23.76%
31.38%
25.16%
5117.43%
137.34%
31.06%
29.83%
29.20%
28.88%
28.18%
25.66%
PAT
1,451.21
1,361.85
1,047.09
-1,899.00
-169.72
941.71
970.04
775.97
924.98
803.78
1,108.80
PAT before Minority Interest
1,451.34
1,361.95
1,047.14
-1,830.85
-89.56
993.65
970.09
775.97
924.99
803.87
1,108.75
Minority Interest
0.13
-0.10
-0.05
-68.15
-80.16
-51.94
-0.05
0.00
-0.01
-0.09
0.05
PAT Margin
9.11%
8.02%
7.86%
-16.08%
-1.47%
7.65%
8.86%
7.29%
9.38%
8.86%
12.21%
PAT Growth
43.71%
30.06%
-
-
-
-2.92%
25.01%
-16.11%
15.08%
-27.51%
 
EPS
51.42
48.26
37.10
-67.29
-6.01
33.37
34.37
27.50
32.78
28.48
39.29

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
10,512.11
8,849.44
7,847.93
9,473.92
9,086.65
7,064.63
6,070.51
5,605.18
5,163.48
4,492.52
Share Capital
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
Total Reserves
10,449.88
8,812.16
7,801.48
9,428.09
9,042.13
7,014.78
6,028.59
5,566.35
5,124.75
4,462.86
Non-Current Liabilities
1,773.05
109.35
-357.23
2,621.45
1,269.61
2,803.62
3,033.01
2,279.94
2,824.12
3,257.81
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
512.70
0.00
3,852.14
2,571.74
3,888.82
4,042.99
3,573.75
4,141.78
4,536.34
Long Term Provisions
176.61
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
6,376.43
5,967.02
5,818.59
4,546.24
4,689.43
4,201.02
4,125.98
4,021.09
3,287.89
2,702.68
Trade Payables
3,743.87
3,051.20
2,535.93
2,000.43
2,288.66
2,237.77
2,125.84
2,220.75
1,869.78
1,743.22
Other Current Liabilities
1,467.94
436.17
1,517.23
1,605.31
1,446.27
885.78
1,001.63
1,013.21
690.60
509.32
Short Term Borrowings
0.00
1,681.49
833.36
350.00
370.00
513.01
442.60
303.02
295.04
187.19
Short Term Provisions
1,164.62
798.16
932.08
590.51
584.50
564.45
555.91
484.11
432.46
262.95
Total Liabilities
18,661.27
14,925.44
13,308.91
17,006.95
15,397.16
14,068.92
13,229.11
11,905.83
11,275.12
10,452.59
Net Block
5,914.54
4,486.82
4,210.16
5,421.76
5,887.25
5,128.85
5,028.56
3,670.25
3,029.55
2,755.09
Gross Block
12,071.85
10,364.92
9,619.64
10,359.59
10,213.47
8,731.58
8,269.83
6,527.27
5,367.95
4,769.92
Accumulated Depreciation
6,157.31
5,878.10
5,409.48
4,937.83
4,326.23
3,602.73
3,241.28
2,857.01
2,338.39
2,014.83
Non Current Assets
7,361.56
5,629.98
5,880.82
6,840.24
7,114.82
6,709.33
6,425.49
5,209.02
4,286.43
3,577.96
Capital Work in Progress
909.13
834.83
661.88
1,189.64
1,009.87
1,381.67
1,221.89
1,398.94
1,121.87
708.11
Non Current Investment
42.36
56.35
789.66
44.57
49.62
24.63
24.59
29.66
14.66
15.69
Long Term Loans & Adv.
492.67
242.74
211.70
180.80
161.38
146.29
123.97
94.36
119.78
98.94
Other Non Current Assets
2.86
9.23
7.42
3.46
6.70
27.89
26.49
15.80
0.56
0.13
Current Assets
11,299.71
9,295.47
7,428.08
8,423.64
8,282.35
7,359.58
6,803.62
6,696.82
6,988.69
6,874.64
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
3,430.78
3,028.53
2,513.05
2,373.62
2,499.83
2,276.83
2,135.62
2,252.07
2,030.59
2,139.05
Sundry Debtors
4,963.35
3,341.95
1,858.41
3,665.17
3,101.14
2,572.05
2,408.96
2,194.59
2,331.81
2,404.32
Cash & Bank
1,176.26
1,705.23
1,659.46
1,160.30
1,411.52
1,139.16
1,111.24
937.76
1,234.69
1,057.66
Other Current Assets
1,729.32
144.97
178.21
316.61
1,269.87
1,371.54
1,147.78
1,312.40
1,391.61
1,273.61
Short Term Loans & Adv.
1,420.90
1,074.79
1,218.95
907.93
972.41
700.49
544.48
547.18
580.83
590.22
Net Current Assets
4,923.28
3,328.44
1,609.49
3,877.39
3,592.92
3,158.56
2,677.63
2,675.73
3,700.80
4,171.96
Total Assets
18,661.27
14,925.45
13,308.90
15,263.88
15,397.17
14,068.91
13,229.11
11,905.84
11,275.12
10,452.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
3,445.03
-827.60
-265.44
625.39
1,108.65
1,131.21
1,392.41
1,324.17
1,648.05
657.43
PBT
1,984.75
1,399.21
569.19
868.45
1,441.25
1,382.47
1,096.08
1,300.63
1,119.33
1,491.43
Adjustment
2,690.42
946.95
1,009.81
1,471.96
787.11
644.82
636.23
329.83
571.28
726.56
Changes in Working Capital
-447.12
-2,493.63
-796.95
-1,074.48
-561.26
-385.84
127.06
136.34
309.06
-861.51
Cash after chg. in Working capital
4,228.04
-147.47
782.05
1,265.93
1,667.09
1,641.45
1,859.37
1,766.81
1,999.67
1,356.48
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-783.01
-680.13
-1,047.49
-640.54
-558.44
-510.24
-466.95
-442.63
-351.61
-699.05
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,283.23
2.09
4,560.89
-528.49
-333.28
-675.24
-783.52
-698.99
-1,013.34
-712.35
Net Fixed Assets
-277.44
-307.30
-234.42
-220.67
-155.36
-184.89
-248.78
455.14
-362.24
-256.09
Net Investments
-7.30
-2,230.12
-2,632.08
-1,773.32
-1,569.44
-2,276.02
-1,445.18
-56.07
-1,345.98
-8.28
Others
-998.49
2,539.51
7,427.39
1,465.50
1,391.52
1,785.67
910.44
-1,098.06
694.88
-447.98
Cash from Financing Activity
-2,708.75
787.04
-3,906.13
-77.46
-520.49
-441.78
-444.66
-738.74
-468.50
543.15
Net Cash Inflow / Outflow
-546.95
-38.46
389.32
19.45
254.88
14.20
164.23
-113.56
166.21
488.24
Opening Cash & Equivalents
1,675.71
1,658.27
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
Closing Cash & Equivalent
1,174.71
1,675.71
1,658.27
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
371.30
313.28
277.46
335.13
321.45
249.60
214.65
198.27
182.62
159.16
ROA
8.11%
7.42%
-11.86%
-0.54%
6.74%
7.11%
6.17%
7.98%
7.40%
11.33%
ROE
14.10%
12.56%
-21.18%
-0.97%
12.33%
14.81%
13.32%
17.21%
16.67%
27.31%
ROCE
20.35%
16.16%
4.88%
4.43%
14.19%
15.30%
14.04%
16.47%
14.77%
20.54%
Fixed Asset Turnover
3.09
2.87
2.77
2.74
2.94
2.97
1.44
1.66
1.80
2.03
Receivable days
43.78
33.06
36.38
43.76
37.24
36.01
78.95
83.73
94.95
97.29
Inventory Days
34.05
35.23
32.19
31.52
31.35
31.90
75.25
79.22
83.59
73.65
Payable days
264.58
237.83
190.23
186.18
191.57
219.98
98.44
97.43
96.28
101.59
Cash Conversion Cycle
-186.74
-169.54
-121.67
-110.90
-122.98
-152.06
55.77
65.53
82.26
69.35
Total Debt/Equity
0.00
0.25
0.13
0.46
0.40
0.67
0.80
0.80
0.90
1.05
Interest Cover
10.51
7.76
1.07
1.69
5.83
4.92
3.90
4.89
4.92
7.28

News Update:


  • Glenmark Pharmaceuticals’ arm submits IND application to USFDA for ISB 2301
    18th Nov 2026, 11:12 AM

    This pentaspecific molecule combines five binding specificities: three tumor-associated antigens, plus T-cell and NK-cell activation

    Read More
  • Glenmark Pharmaceuticals’ arm launches Axitinib Tablets
    16th Nov 2026, 10:39 AM

    This product is an Authorized Generic version of INLYTA tablets

    Read More
  • Glenmark Pharma reports 57% fall in Q2 consolidated net profit
    6th Nov 2026, 14:12 PM

    The total consolidated income of the company has decreased by 31.97% at Rs 4,249.87 crore for Q2FY27

    Read More
  • Glenmark Pharma. - Quarterly Results
    6th Nov 2026, 00:00 AM

    Read More
  • Glenmark Pharmaceuticals’ arm launches Adapalene Gel USP in new pump packs
    6th Oct 2026, 10:12 AM

    Glenmark’s Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin Gel, 0.1%

    Read More
  • Glenmark Pharmaceuticals gets EIR with VAI status for Goa facility
    23rd Sep 2026, 10:12 AM

    The inspection was conducted at the company’s manufacturing facility from June 22, 2026 to June 30, 2026

    Read More
  • Glenmark Pharmaceuticals’ arm launches RYALTRIS Nasal Spray in Brazil
    11th Sep 2026, 10:22 AM

    The launch follows regulatory approval granted by the Brazilian Health Regulatory Agency, Agencia Nacional de Vigilancia Sanitaria earlier this year

    Read More
  • Glenmark Pharmaceuticals’ arm launches Calcium Gluconate Injection
    21st Aug 2026, 11:28 AM

    The Calcium Gluconate Injection, 1,000 mg/10 mL, 5,000 mg/50 mL and 10,000 mg/100 mL market achieved annual sales of around $69.9 million.

    Read More
  • Glenmark Pharma gets USFDA’s nod for Fluticasone Propionate Nasal Spray
    20th Aug 2026, 09:23 AM

    According to IQVIA sales data for the 12-month period ending June 2026, the Flonase Nasal Spray market achieved annual sales of around $295.2 million

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.